VNRX

VolitionRx Limited

Price Chart

Latest Quote

$1.46

+0.07 (+5.04%)

Current Price

Previous Close	$1.39
Open	$1.36
Day High	$1.48
Day Low	$1.32
Volume	148,417

Fetched: 2026-06-11T20:55:46

Stock Information

Shares Outstanding	11.59M
Total Debt	$11.70M
Cash Equivalents	$3.10M
Revenue	$2.47M
Net Income	$-24.60M
Sector	Healthcare
Industry	Medical Devices
Market Cap	$15.99M
EPS (TTM)	$-4.25
Exchange	ASE

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$18.71M
Sales	$2.47M
Income	$-24.60M
Book/sh	$-5.45
Cash/sh	$0.27
Employees	67

Financial Ratios

Quick Ratio	0.25
Current Ratio	0.33

Returns & Margins

ROA	-153.54%
Gross Margin	100.00%
Operating Margin	-542.99%

Ownership

Insider Ownership	8.62%
Institutional Ownership	20.80%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.20
P/S	6.48
P/B	-0.25

Analyst Data

Recommendation	strong_buy
Target Price	$20.21

Technical Indicators

SMA20	$2.21
SMA50	$2.62
SMA200	$6.09
RSI	5.13
ATR	0.2600

Shares Float	6.66M
Short Float	4.77%
Short Ratio	1.28
Volatility	1.04
Rel Volume	0.90

Performance History

Week	-22.91%
Month	-41.53%
Quarter	-63.68%
6 Months	-75.36%
YTD	-74.44%
Year	-87.68%
3 Years	-95.66%
5 Years	-98.06%
10 Years	-97.88%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-12	$1.38	319,800
2026-06-11	$1.46	156,500
2026-06-10	$1.39	230,400
2026-06-09	$1.36	378,800
2026-06-08	$1.39	1,316,900
2026-06-05	$1.79	474,800
2026-06-04	$2.00	482,300
2026-06-03	$2.08	473,800
2026-06-02	$2.32	248,600
2026-06-01	$2.65	250,300
2026-05-29	$2.67	156,600
2026-05-28	$2.88	277,600
2026-05-27	$2.94	560,100
2026-05-26	$2.94	231,700
2026-05-22	$3.13	514,200
2026-05-21	$2.70	281,200
2026-05-20	$2.49	125,700
2026-05-19	$2.35	219,800
2026-05-18	$2.28	260,500
2026-05-15	$2.00	174,400
2026-05-14	$2.20	106,300
2026-05-13	$2.36	232,000

About VolitionRx Limited

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

📰 Latest News

VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts

Insider Monkey • 2026-05-24T11:49:07Z

VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...

GuruFocus.com • 2026-05-15T23:02:07Z

VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com • 2026-04-03T01:01:42Z

VolitionRx Limited Q4 2025 Earnings Call Summary

Moby • 2026-04-01T12:30:00Z

VolitionRx announces automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems

TipRanks • 2026-03-07T13:18:03Z

VolitionRX Ltd (VNRX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Revenue ...

GuruFocus.com • 2025-11-14T21:01:07Z

VolitionRx Limited Q3 2025 Earnings Call Summary

Moby • 2025-11-14T13:30:00Z

VolitionRX: Q3 Earnings Snapshot

Associated Press Finance • 2025-11-13T22:41:08Z

VolitionRX Ltd (VNRX) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Advances ...

GuruFocus.com • 2025-08-16T07:03:11Z

VolitionRX: Q2 Earnings Snapshot

Associated Press Finance • 2025-08-14T21:06:43Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$1,727,384	$1,233,511	$775,302	$306,392
Operating Revenue	$1,727,384	$1,233,511	$775,302	$306,392
Expenses
Interest Expense	$2,489,339	$340,362	$221,622	$173,087
Total Expenses	$22,949,440	$28,155,113	$36,548,546	$30,857,039
Other Income Expense	$207,466	$-5,968	$224,468	-
Net Non Operating Interest Income Expense	$-2,488,739	$-330,415	$-128,298	$-47,822
Interest Expense Non Operating	$2,489,339	$340,362	$221,622	$173,087
Operating Expense	$22,949,440	$28,155,113	$36,548,546	$30,857,039
Other Operating Expenses	$-516,515	$-103,368	$-214,451	$-1,229,425
Selling And Marketing Expense	$717,972	$922,602	$1,012,868	$1,053,807
General And Administrative Expense	$12,483,639	$12,716,963	$15,906,556	$15,350,860
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-23,357,027	$-26,967,836	$-35,319,078	$-30,268,793
Net Interest Income	$-2,488,739	$-330,415	$-128,298	$-47,822
Interest Income	$600	$9,947	$93,324	$125,265
Normalized Income	$-23,564,493	$-26,961,868	$-35,543,546	$-30,268,793
Net Income From Continuing And Discontinued Operation	$-23,357,027	$-26,967,836	$-35,319,078	$-30,268,793
Total Operating Income As Reported	$-21,738,571	$-27,024,970	$-35,987,695	$-31,780,072
Net Income Common Stockholders	$-23,357,027	$-26,967,836	$-35,319,078	$-30,268,793
Net Income	$-23,357,027	$-26,967,836	$-35,319,078	$-30,268,793
Net Income Including Noncontrolling Interests	$-23,503,329	$-27,257,985	$-35,677,074	$-30,598,469
Net Income Continuous Operations	$-23,503,329	$-27,257,985	$-35,677,074	$-30,598,469
Pretax Income	$-23,503,329	$-27,257,985	$-35,677,074	$-30,598,469
Special Income Charges	$1,829	$-34,731	$-15,843	$0
Interest Income Non Operating	$600	$9,947	$93,324	$125,265
Operating Income	$-21,222,056	$-26,921,602	$-35,773,244	$-30,550,647
Depreciation Amortization Depletion Income Statement	$183,045	$212,430	$292,050	$348,808
Depreciation And Amortization In Income Statement	$183,045	$212,430	$292,050	$348,808
Per Share
Diluted EPS	$-4.40	$-6.20	$-10.00	$-11.00
Basic EPS	$-4.40	$-6.20	$-10.00	$-11.00
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-20,005,055	$-25,572,723	$-34,266,643	$-29,235,434
Total Unusual Items	$207,466	$-5,968	$224,468	$0
Total Unusual Items Excluding Goodwill	$207,466	$-5,968	$224,468	$0
Reconciled Depreciation	$1,216,401	$1,338,932	$1,413,277	$1,189,948
EBITDA (Bullshit earnings)	$-19,797,589	$-25,578,691	$-34,042,175	$-29,235,434
EBIT	$-21,013,990	$-26,917,623	$-35,455,452	$-30,425,382
Diluted Average Shares	$5,341,607	$4,326,558	$3,561,728	$2,767,520
Basic Average Shares	$5,341,607	$4,326,558	$3,561,728	$2,767,520
Diluted NI Availto Com Stockholders	$-23,357,027	$-26,967,836	$-35,319,078	$-30,268,793
Minority Interests	$146,302	$290,149	$357,996	$329,676
Gain On Sale Of Ppe	$1,829	$-34,731	$-15,843	$0
Gain On Sale Of Security	$205,637	$28,763	$240,311	-
Research And Development	$10,081,299	$14,406,486	$19,551,523	$15,332,989
Selling General And Administration	$13,201,611	$13,639,565	$16,919,424	$16,404,667
Other Gand A	$3,508,351	$3,356,795	$3,695,735	$3,441,520
Salaries And Wages	$8,975,288	$9,360,168	$12,210,821	$11,909,340

Fetched: 2026-06-09

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-34,563,097	$-25,221,367	$-7,826,141	$-2,685,496
Total Assets	$6,901,227	$9,399,523	$27,950,498	$18,295,054
Total Non Current Assets	$4,840,302	$5,342,715	$6,096,403	$6,122,909
Goodwill And Other Intangible Assets	$316,704	$313,747	$23,886	$110,505
Other Intangible Assets	$316,704	$313,747	$23,886	$110,505
Current Assets	$2,060,925	$4,056,808	$21,854,095	$12,172,145
Other Current Assets	$192,409	$343,145	$360,125	$447,566
Prepaid Assets	$433,680	$338,660	$521,370	$784,920
Receivables	$317,808	$110,574	$242,617	$72,609
Accounts Receivable	$317,808	$110,574	$242,617	$72,609
Allowance For Doubtful Accounts Receivable	$0	$-31,735	-	-
Gross Accounts Receivable	$317,808	$142,309	-	-
Cash Cash Equivalents And Short Term Investments	$1,117,028	$3,264,429	$20,729,983	$10,867,050
Cash And Cash Equivalents	$1,117,028	$3,264,429	$20,729,983	$10,867,050
Debt
Net Debt	$9,448,572	$1,548,640	-	-
Total Debt	$11,464,730	$5,820,585	$5,857,836	$4,973,340
Long Term Debt And Capital Lease Obligation	$7,851,171	$4,691,870	$4,402,936	$3,615,463
Long Term Debt	$7,256,754	$3,952,846	$3,624,860	$2,779,240
Current Debt And Capital Lease Obligation	$3,613,559	$1,128,715	$1,454,900	$1,357,877
Current Debt	$3,308,846	$860,223	$1,207,007	$1,066,700
Other Current Borrowings	$3,308,846	$860,223	$1,207,007	$1,066,700
Liabilities
Total Liabilities Net Minority Interest	$42,494,038	$35,507,259	$36,662,720	$21,422,016
Total Non Current Liabilities Net Minority Interest	$30,263,285	$27,716,512	$27,719,043	$4,035,929
Tradeand Other Payables Non Current	$473,652	$361,242	$422,707	$420,466
Non Current Deferred Liabilities	$21,938,462	$22,663,400	$22,893,400	-
Current Liabilities	$12,230,753	$7,790,747	$8,943,677	$17,386,087
Other Current Liabilities	$934,720	$97,886	$126,649	-
Current Deferred Liabilities	$353,846	$230,000	$106,600	$10,000,000
Payables And Accrued Expenses	$7,328,628	$6,334,146	$7,255,528	$6,028,210
Payables	$3,116,800	$2,857,243	$3,326,767	$3,155,963
Other Payable	$198,032	$91,065	$115,480	$112,955
Accounts Payable	$2,918,768	$2,766,178	$3,211,287	$3,043,008
Equity
Common Stock Equity	$-34,246,393	$-24,907,620	$-7,802,255	$-2,574,991
Total Equity Gross Minority Interest	$-35,592,811	$-26,107,736	$-8,712,222	$-3,126,962
Stockholders Equity	$-34,246,393	$-24,907,620	$-7,802,255	$-2,574,991
Gains Losses Not Affecting Retained Earnings	$-295,071	$385,631	$243,940	$227,097
Other Equity Adjustments	$-295,071	$385,631	$243,940	$227,097
Retained Earnings	$-252,901,370	$-229,544,343	$-202,576,507	$-167,257,429
Other
Ordinary Shares Number	$6,288,988	$4,804,874	$4,094,916	$2,893,668
Share Issued	$6,288,988	$4,804,874	$4,094,916	$2,893,668
Tangible Book Value	$-34,563,097	$-25,221,367	$-7,826,141	$-2,685,496
Invested Capital	$-23,680,793	$-20,094,551	$-2,970,388	$1,270,949
Working Capital	$-10,169,828	$-3,733,939	$12,910,418	$-5,213,942
Capital Lease Obligations	$899,130	$1,007,516	$1,025,969	$1,127,400
Total Capitalization	$-26,989,639	$-20,954,774	$-4,177,395	$204,249
Minority Interest	$-1,346,418	$-1,200,116	$-909,967	$-551,971
Additional Paid In Capital	$218,824,268	$204,154,994	$194,448,414	$164,397,468
Capital Stock	$125,780	$96,098	$81,898	$57,873
Common Stock	$125,780	$96,098	$81,898	$57,873
Non Current Deferred Revenue	$21,938,462	$22,663,400	$22,893,400	-
Long Term Capital Lease Obligation	$594,417	$739,024	$778,076	$836,223
Current Deferred Revenue	$353,846	$230,000	$106,600	$10,000,000
Current Capital Lease Obligation	$304,713	$268,492	$247,893	$291,177
Current Accrued Expenses	$4,211,828	$3,476,903	$3,928,761	$2,872,247
Net PPE	$4,523,598	$5,028,968	$6,072,517	$6,012,404
Accumulated Depreciation	$-6,393,548	$-4,974,450	$-4,189,089	$-3,312,863
Gross PPE	$10,917,146	$10,003,418	$10,261,606	$9,325,267
Other Properties	$5,538,152	$5,199,984	$5,302,757	$4,809,681
Machinery Furniture Equipment	$1,056,767	$1,060,842	$1,103,334	$1,015,334
Buildings And Improvements	$4,181,415	$3,618,386	$3,723,047	$3,371,464
Land And Improvements	$140,812	$124,206	$132,468	$128,788

Fetched: 2026-06-09

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-19,772,892	$-26,467,476	$-19,146,748	$-16,847,924
Operating Activities
Operating Cash Flow	$-19,683,334	$-25,893,624	$-18,062,999	$-15,277,742
Cash Flow From Continuing Operating Activities	$-19,683,334	$-25,893,624	$-18,062,999	$-15,277,742
Operating Gains Losses	$-207,466	$5,968	$-224,468	-
Investing Activities
Capital Expenditure	$-89,558	$-573,852	$-1,083,749	$-1,570,182
Investing Cash Flow	$-89,558	$-573,852	$-1,083,749	$-1,570,182
Cash Flow From Continuing Investing Activities	$-89,558	$-573,852	$-1,083,749	$-1,570,182
Financing Activities
Issuance Of Capital Stock	$11,170,410	$8,592,177	$28,388,036	$6,736,444
Financing Cash Flow	$17,092,858	$8,657,254	$28,982,685	$6,938,032
Cash Flow From Continuing Financing Activities	$17,092,858	$8,657,254	$28,982,685	$6,938,032
Net Other Financing Charges	$-98,991	$-168,152	$-200,659	$-7,691
Net Common Stock Issuance	$11,170,410	$8,592,177	$28,356,264	$6,736,444
Common Stock Issuance	$11,170,410	$8,592,177	$28,388,036	$6,736,444
Repurchase Of Capital Stock	-	$0	$-31,772	$0
Other
Repayment Of Debt	$-1,761,518	$-1,135,273	$-1,027,797	$-1,313,819
Issuance Of Debt	$7,782,957	$1,368,502	$1,854,877	$1,523,098
Interest Paid Supplemental Data	$280,718	$340,362	$221,622	$173,110
End Cash Position	$1,117,028	$3,264,429	$20,729,983	$10,867,050
Beginning Cash Position	$3,264,429	$20,729,983	$10,867,050	$20,581,313
Effect Of Exchange Rate Changes	$532,633	$344,668	$26,996	$195,629
Changes In Cash	$-2,680,034	$-17,810,222	$9,835,937	$-9,909,892
Net Issuance Payments Of Debt	$6,021,439	$233,229	$827,080	$209,279
Net Long Term Debt Issuance	$6,021,439	$233,229	$827,080	$209,279
Long Term Debt Payments	$-1,761,518	$-1,135,273	$-1,027,797	$-1,313,819
Long Term Debt Issuance	$7,782,957	$1,368,502	$1,854,877	$1,523,098
Net Intangibles Purchase And Sale	$0	$-296,353	$0	-
Purchase Of Intangibles	$0	$-296,353	$0	-
Net PPE Purchase And Sale	$-89,558	$-277,499	$-1,083,749	$-1,570,182
Purchase Of PPE	$-89,558	$-277,499	$-1,083,749	$-1,570,182
Change In Working Capital	$-885,798	$-1,249,082	$14,135,721	$11,016,120
Change In Other Working Capital	$-601,092	$-106,600	$13,000,000	$9,987,488
Change In Other Current Liabilities	$-262,018	$-257,204	$-258,853	$-232,695
Change In Other Current Assets	$150,736	$16,980	$87,441	$351,514
Change In Payables And Accrued Expense	$128,830	$-1,217,013	$1,213,249	$548,427
Change In Payable	$128,830	$-1,217,013	$1,213,249	$548,427
Change In Account Payable	$77,977	$-1,217,013	$1,224,743	$548,611
Change In Prepaid Assets	$-95,020	$182,710	$263,550	$433,995
Change In Receivables	$-207,234	$132,045	$-169,666	$-72,609
Changes In Account Receivables	$-207,234	$132,045	$-169,666	$-72,609
Other Non Cash Items	$1,957,147	-	-	-
Stock Based Compensation	$1,739,711	$1,268,543	$2,289,545	$3,114,659
Depreciation Amortization Depletion	$1,216,401	$1,338,932	$1,413,277	$1,189,948
Depreciation And Amortization	$1,216,401	$1,338,932	$1,413,277	$1,189,948
Depreciation	$1,216,401	$1,338,932	$1,413,277	$1,189,948
Gain Loss On Investment Securities	$-205,637	$-28,763	$-240,311	-
Gain Loss On Sale Of PPE	$-1,829	$34,731	$15,843	$0
Net Income From Continuing Operations	$-23,503,329	$-27,257,985	$-35,677,074	$-30,598,469
Common Stock Payments	-	$0	$-31,772	$0
Income Tax Paid Supplemental Data	-	-	-	$0
Sale Of PPE	-	-	-	-

Fetched: 2026-06-09